WuXi Biologics Enters Licensing Deal with Hangzhou DAC and Aadi Bio for Preclinical ADC Portfolio
China-based Contract Research and Development Organization (CRDMO) WuXi Biologics (HKG: 2269) has announced a strategic...
DAC Biotechnology
DAC Biotech’s DXC005 ADC Doses First Patient in Beijing Cancer Hospital Trial
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing of its...
Hangzhou DAC Biotech Doses First Patient in DXC007 AML Study
China-based Hangzhou DAC Biotech Co., Ltd announced the first patient enrollment and dosing in a...
Hangzhou DAC Bio Partners with Janssen on ADC Development Deal
China-based Hangzhou DAC Biotech Co., Ltd announced a licensing agreement with Janssen Pharmaceuticals Inc., a...
Kelun Pharma’s SKB264 ADC Receives Breakthrough Therapy Designation for TNBC
The Center for Drug Evaluation (CDE) website indicates that Sichuan Kelun Pharmaceutical Co., Ltd’s (SHE:...